We are proud to share our latest contribution to the field of specialty chemicals, where we explore the promising role of bile acids (BAs) as functional excipients in drug delivery systems.
The Need for Next-Generation Excipients
In pharmaceutical development, excipients such as cellulose derivatives, surfactants, and lipids have long been employed to improve drug solubility and stability. However, these traditional options often fall short when applied to:
- Biologics such as peptides and proteins
- Poorly soluble compounds with limited aqueous solubility
This challenge has accelerated the demand for bioactive and multifunctional excipients capable of supporting the next generation of therapies, including advanced biologics and complex molecules.
Why Bile Acids?
Bile acids are naturally occurring molecules that evolved to optimize lipid digestion and absorption in the human body. Their unique dual hydrophilic–lipophilic character allows them to:
- Interact dynamically with drug molecules
- Enhance permeation across biological membranes
- Improve the bioavailability of difficult-to-formulate compounds
These properties make bile acids a highly attractive platform for designing innovative drug delivery strategies that go beyond the limitations of conventional excipients.
Applications in Modern Drug Delivery
Recent research highlights the potential of bile acids in:
- Oral delivery of peptides and biologics, where absorption is typically low
- Formulations for poorly soluble small molecules
- Targeted drug delivery systems, leveraging their membrane interaction properties
By acting not only as solubilizers but also as functional enhancers of permeability and stability, bile acids are poised to play a central role in the future of pharmaceutical innovation.
Driving Pharmaceutical Innovation at ICE Pharma
At ICE Pharma, we are committed to advancing the use of functional excipients that meet the evolving challenges of drug development. Bile acids represent a significant step forward in this mission, opening new opportunities for specialty chemical applications in the pharmaceutical industry.
We extend a special thank you to Madalina Cociorb, PhD, Business Development Specialist at ICE Pharma, for her valuable contribution to this article and for her ongoing dedication to advancing innovation in drug delivery.